There are 3397 resources available
Discussion led by Chair
Presenter: Silke Gillessen
Session: All you want to know about advanced prostate cancer as we finally enter the era of biomarker-triggered treatment
Resources:
Slides
Webcast
Adjuvant only
Presenter: Enriqueta Felip
Session: Adjuvant or neoadjuvant immunotherapy or both in localised NSCLC
Resources:
Slides
Webcast
Neo adjuvant only
Presenter: Rafal Dziadziuszko
Session: Adjuvant or neoadjuvant immunotherapy or both in localised NSCLC
Resources:
Slides
Webcast
Neo adjuvant follow by adjuvant
Presenter: Federico Cappuzzo
Session: Adjuvant or neoadjuvant immunotherapy or both in localised NSCLC
Resources:
Slides
Webcast
First voting
Presenter: Tony S.K. Mok
Session: Adjuvant or neoadjuvant immunotherapy or both in localised NSCLC
Resources:
Slides
Webcast
Perspective from the Chair
Presenter: Tony S.K. Mok
Session: Adjuvant or neoadjuvant immunotherapy or both in localised NSCLC
Resources:
Slides
Webcast
Second voting
Presenter: Tony S.K. Mok
Session: Adjuvant or neoadjuvant immunotherapy or both in localised NSCLC
Resources:
Slides
Webcast
855MO - Adjuvant immunotherapy after salvage surgery in head and neck cancer squamous cell carcinoma (HNSCC): Phase II trial evaluating the efficacy and the toxicity of Nivolumab (ADJORL1)
Presenter: Caroline Even
Session: Mini oral session - Head and neck cancer
Resources:
Abstract
Slides
Webcast
1914MO - The clinico-radiological outcome of desmoid type-fibromatosis after discontinuing the sorafenib treatment in responders: Single-arm phase II clinical trial
Presenter: Sameer Rastogi
Session: Mini oral session - Sarcoma
Resources:
Abstract
Slides
Webcast
Introduction and scientific background
Presenter: Raffaele Califano
Session: Open questions in immunotherapy for advanced NSCLC: Duration of IO, combinations and rechallenge
Resources:
Slides
Webcast